Benign Hematology   

Questions discussed in this category



In the setting of no personal or family history and no other risk factors for thrombosis, is systemic anticoagulation warranted if local treatments (e...

This is in the setting of a patient who is now on ruxolitinib with rising leukocytosis and thrombocytosis, but cannot be on aspirin due to recent blee...

For example, for outpatients or resource-limited settings with a moderate probability 4-T score (but low clinical suspicion), would you ever consider ...

e.g. in the setting of using prophylactic heparin in the past but now requiring therapeutic anticoagulation

Aside from addressing the underlying case, is there a role for phlebotomy in secondary polycythemia such as in COPD or post-renal transplant erythrocy...

Please also discuss the type and duration of anticoagulation.

Also is there value in using voxelotor for the purpose of reducing hemolysis, and if so what parameters do you use to determine when to initiate voxel...

Is there a particular sequence you would adjust contributing antirejection or antimicrobial medications? Is the use of G-CSF appropriate and at what c...

Hydroxyurea is demonstrated to reduce complications and improve long-term outcomes in severe genotypes HbSS and sickle beta0 thalassemia. What clinica...

What if the patient is triple-positive or has continued seropositivity on repeat lab testing? What is the appropriate interval of monitoring and does ...

Provoked or unprovoked VTE: Do you use D-Dimer (or even repeat imaging to reassess residual clot) in any capacity to guide anticoagulation duration? E...

Have you used anticoagulants other than coumadin? Or is that the only appropriate agent given monitoring is based on PT/INR?

Do you ever recheck JAK2/CALR/MPL/BCR-ABL? Would you recommend a bone marrow biopsy? Is cytoreductive therapy indicated?

Is there a role for aspirin or hydroxyurea? Do you perform phlebotomy, and if so, what goals?

While low-dose aspirin for primary thrombosis prevention in aPL without APS is not typically recommended outside cardiovascular prevention guidelines ...

While building a trusting patient-physician relationship, what therapies could be discussed that may be aligned with naturopathic medicine? (i.e. L-gl...

Is this a reason to start hydrea? Would you give oral iron after adequate control on hydrea?

Patient with ferritin level <1000 ng/mL and no evidence of end-organ damage

While there are many factors involving:- type (DVT vs PE, unprovoked vs provoked) and severity of venous thromboembolism (VTE) size- duration of antic...

If all work-up including peripheral flow, bone marrow biopsy, PET-CT returns negative, what additional management (if any) would be recommended?

Does manipulation of blood products (leukoreduction, irradiated) affect your approach? There is growing evidence that routine premedication (at least ...

While follow up ultrasound is not usually recommended in provoked DVT, it often is done either for other reasons or by other physicians. Would this in...

While this is a known risk factor for venous [Meijers et al NEJM 2000] and potentially arterial [Yang et al, Am J Clin Pathol 2006] thrombosis, it is ...

Are there major differences in standard conditioning and/or GVHD prophylaxis regimens utilized? Does the non-relapse mortality different significantl...

How often do you monitor ADAMTS-13 levels off therapy?

For example, do we prefer one regimen over the other in patients with a bleeding history or who have relapsed after a lengthy remission?

Do you recommend therapeutic phlebotomy to a certain Hct goal? Any strong evidence for thromboembolic risk related to erythrocytosis or if this is mit...

Is there any difference between anticoagulants in this clinical context (e.g. anti-Xa inhibitors vs warfarin vs LMWH)?

What are your target goals during transfusion, either prophylactically or during acute complication? Does your management change between vaginal deliv...

- Dialysis catheter used for hemodialysis- RIJ thrombus in dialysis catheter was incidentally found- Patient asymptomatic with no prior history of VTE...

While benefits outweigh known harms and limited data, do you worry about vaccination in patients with a history of or active autoimmune cytopenias (e....

Assuming the patient is a candidate for all anticoagulation options (no mechanical valve, antiphospholipid syndrome, patient-specific contraindication...

While thrombophilia testing is not routinely recommended prior to starting OCPs, how about after the development of a VTE?

Especially in a triple-positive patient with an acute ischemic stroke who may have urgency for anticoagulation with high bleeding risk and severe thro...

While the CKD population is at high thrombotic and bleeding risk, would you consider anticoagulating a patient prophylactically if they had a history ...

The patient who has not responded to steroids, rituximab/bendamustine, and splenectomy?

In a patient with severe factor XII deficiency with a baseline prolonged PTT, what is the best method to monitor their ACT or heparin levels when on c...

Would you give a trial of IST first or immediately refer for SCT if the patient has matched siblings?

Would you consider high-dose dexamethasone (deliberating adverse effects of antenatal steroids) or move to next-line therapies?

Has your medical practice taken any steps either in community outreach or within the clinic to show support for this medically vulnerable population, ...

For a patient with low ferritin, but high TSAT?

Ref: EINSTEIN-CHOICE and AMPLIFY-EXT Would you approach this differently in patients with inherited thrombophilias?

For example, in cold agglutinin disease or AIHA, antibodies can be detected via DAT, but are often not observed on assays for monoclonal gammopathies.

During the Stimate recall, how are we performing DDAVP challenges for newly diagnosed hemophilia A or von Willebrand disease?

In low-risk patients (age < 40) or patients with very obvious causes of blood loss or iron deficiency (menorrhagia, pregnancy), do you routinely pe...

Given the high cost of eculizumab, are there patient characteristics that inform which patients, if any, should be on indefinite therapy versus a time...

Such as a patient who cannot tolerate oral iron and has had a anaphylaxis to intravenous iron

For example, a patient with hypogonadism unless it matters which organ is involved. Are other markers of iron storage useful in guiding therapy?

For example, a patient on cytoreductive therapy and aspirin BID, but suffers an arterial event, or a patient who is already on therapeutic anticoagula...

In a patient with a medical or personal indication to induce oligomenorrhea/amenorrhea, how would you manage OCP therapy if a patient develops a VTE d...

If autoimmune neutropenia already suspected, is this test informative or unnecessary?

What is the lowest level you have seen with uncomplicated or complicated crises?

Do you go straight to TMPRSS2 genetic testing or what other lab testing (e.g. hepcidin) could be helpful?

There are various formulations of intravenous iron; each with varying costs, test dose requirement, elemental dose, and number or time of infusions ne...

If there are a low-risk patients who can be monitored, how would you do so? If unprovoked, would you consider stopping anticoagulation?

Should we use a different dose in critically ill patients in the ICU? When should we consider intermediate-dose anticoagulation?

Is there a preferred strategy of transfusional support versus reduced-dose anticoagulation during the duration of thrombocytopenia?

While L-glutamine has minimal side effects and would likely be added after hydrea, how do you decide between the use of voxelotor and crizanlizumab?

Rituximab has entered the treatment algorithm in the first-line setting for the initial treatment of TTP. However, in remission, the role of adjuvant ...

Does your opinion change based on the specific underlying inherited thrombophilia? The original case was a central retinal artery occlusion in a patie...

Especially in a patient without hemophilia or thrombosis history?

Would you offer this routinely or only if specific complications arise, such as distal emboli?

In patients who are intolerant to hydroxyurea, anagrelide and interferon


Papers discussed in this category


Blood,

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2016-04

Blood, 2018 Jul 12

Ann. Intern. Med., 2019 Oct 15

Blood Transfus, 2018 Oct 24

J Thromb Haemost, 2018 May 08

AJR Am J Roentgenol,

Blood, 2015-05-28

Blood Adv, 2020 Jan 28

Blood, 2015 Aug 24

Blood, 2008-05-15

The New England journal of medicine, 2019-02-21

J Thromb Haemost, 2019 Jul 28

N Engl J Med, 2018 Dec 04

The New England journal of medicine, 2017-02-02

Blood, 2009 Nov 10

Chest, 1975-12

Clin Nephrol,

Clinical immunology (Orlando, Fla.), 2019-09

Seminars in arthritis and rheumatism, 2019-08

American journal of hematology, 2011-10

The American journal of medicine, 2017-12

American journal of hematology, 2018-05

Am J Hematol, 2020 Jun 29

Am J Hematol, 2019 Sep

Am J Hematol, 2018 Jun

JAMA,

N Engl J Med,

J Vasc Interv Radiol, 2020 Sep 09

Blood, 2015 Dec 22

Contraception, 2016 May 03

BMJ, 2008 May 20

Circulation,

Blood, 2017 Jan 19

Blood Cancer J, 2018 Feb 09

Blood, 2017 May 08

Journal of thrombosis and haemostasis : JTH, 2018-06-07

American journal of hematology, 2008-08

Blood, 2010-07-22

Am J Gastroenterol,

Blood, 2017-07-20

Clin J Am Soc Nephrol, 2016 Oct 31

Blood, 2020 Dec 03

Rheumatol Int, 2019 Apr 30

Clin Exp Rheumatol, 2012 Sep 25

Wien Klin Wochenschr,

Leukemia, 2009-05

J Rheumatol, 2006 Jul 01

Semin Arthritis Rheum,

Haematologica, 2020

Nature, 2019-03

Blood, 2018 May 02

Blood, 2020 Sep 10

Blood Adv,

Journal of thrombosis and haemostasis : JTH, 2013-04-10

J Thromb Haemost, 2009 Aug 19

Clin Appl Thromb Hemost, 2018 Jun 19

Am J Prev Med,

J Natl Med Assoc,

J Adv Nurs, 2015 Sep 09

Issues Ment Health Nurs, 2018 Apr 13

JAMA Netw Open, 2020 May 01

Emerg Infect Dis, 2020 Jul 08

Blood, 2013-12-05

Blood Adv,

Blood,

American journal of hematology, 2016-01

The Lancet. Haematology, 2015-09

Haematologica, 2017-07

Blood, 2018 Jun 13

Blood, 2010 Jul 15

PLoS One, 2021 Apr 08

Ann Rheum Dis,

Transfus Med Rev,

Blood,

Am J Kidney Dis, 2019 Aug 05

Blood, 2016-01-21

Seminars in hematology, 2013-07

N Engl J Med, 2021 Apr 14

J Pharm Pract, 2019 Mar 27

European journal of haematology, 2017-04

J Allergy Clin Immunol Pract, 2021 Feb 03

Eur J Haematol, 2020 May 18

Br J Haematol, 2019 Nov 13

Br J Haematol, 2021 Jun 08

Medicine (Baltimore),

Ann Oncol, 2021 Mar 18

Semin Hematol,

Am J Hematol, 2021 Jun 29

Blood, 2010-11-04

Pediatric blood & cancer, 2014-05

British journal of haematology, 2015-05

Oman Med J, 2020 Nov 07

Pediatr Blood Cancer, 2020 Sep 08

Blood Adv,

Hemoglobin, 2021 May 24

Thromb Res, 2021 Jun 25

Blood, 2016-07-14

Blood, 2016 Sep 26

Expert Rev Hematol, 2019 Jul 05

J Thromb Thrombolysis,

Transfusion, 2020 Sep 24

Lancet Haematol,

Circulation, 2012-09-25

BMJ, 2021 Jun 09

Haematologica, 2010-07

Exp Hematol, 2008 Nov

Blood, 2008-07-15

N Engl J Med, 2017 Jun 1

Ann Intern Med,

Leukemia, 2021 Apr 28

J Am Heart Assoc, 2020 Nov 23

Am J Hematol,